HRT Financial’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

HRT Financial’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,236	Closed	-$6K	–	4105
2022 Q1	$6K	Buy	1,236 +118	+11%	+$742	﹤0.01%	2954
2021 Q4	$6K	Buy	+1,118	New	+$9.5K	﹤0.01%	3049
2021 Q1	–	Sell	-1,033	Closed	-$37K	–	3337
2020 Q4	$37K	Buy	+1,033	New	+$37.4K	﹤0.01%	1713

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial's EVFM Position: Q2 2022 in Review

HRT Financial sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,236 shares — an estimated $6K sold.

HRT Financial first reported a position in EVFM in Q4 2020 and held it in 3 quarters. The position peaked at $37K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

HRT Financial reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
HRT Financial sold 1,236 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $6K.
HRT Financial first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
HRT Financial's Evofem Biosciences, Inc. Common Stock position peaked at $37K in Q4 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on HRT Financial's 13F filing for Q2 2022, filed 12 Aug 2022.